Secarna Pharmaceuticals 和 Orbit Discovery 合作开发肽结合靶向 ASO 疗法。 Secarna Pharmaceuticals and Orbit Discovery partner to develop peptide-conjugated targeted ASO therapeutics.

Secarna Pharmaceuticals 和 Orbit Discovery 合作开发肽偶联靶向反义寡核苷酸 (ASO) 疗法，将 Secarna 在靶向 ASO 方面的能力扩展到抗体和糖分子之外。 Secarna Pharmaceuticals and Orbit Discovery partner to develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics, expanding Secarna's capabilities in targeted ASOs beyond antibodies and sugar molecules. 此次合作利用 Orbit 在肽发现方面的专业知识及其基于珠子的肽展示引擎来识别、筛选和选择环状肽，可能为更广泛的疾病提供新的治疗选择。 The collaboration leverages Orbit's expertise in peptide discovery and its bead-based peptide display engine for the identification, screening, and selection of cyclic peptides, potentially offering new treatment options for a wider range of diseases.